RGNX
insider transactionsREGENXBIO Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-20.4K
0 buy · 20.4K sell
Net value · 365d
-$221.7K
$0 in · $221.7K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
2
0 buy · 20.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +44%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +2%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Grant·A
Director
$0
46.6K sh
Own New
-
Grant·A
Director
$0
9.8K sh
Own +51%
-
Sell·S
Chief Medical Officer · 10b5-1
$168.7K
15.3K sh · $11.02
Own -6%
-
Grant·A
Director
$0
24.4K sh
Own +10%
-
Sell·S
Chief Medical Officer · 10b5-1
$53.0K
5.1K sh · $10.35
Own -2%
-
Other·F
Chief Medical Officer
$58.8K
5.3K sh · $11.16
Own -2%
-
Other·F
Chief Strategy & Legal Officer
$52.5K
4.7K sh · $11.16
Own -2%
-
Exercise·M
Director
$0
225.0K sh
Own New
-
Other·F
Director
$3.0M
221.8K sh · $13.41
Own -31%
-
Exercise·M
Director
$2.9M
225.0K sh · $13.09
Own +47%
-
Grant·A
Curran Simpson KEY
Chief Executive Officer
$0
233.7K sh
Own New
-
Grant·A
Curran Simpson KEY
Chief Executive Officer
$0
144.9K sh
Own +73%
-
Grant·A
Chief Medical Officer
$0
35.4K sh
Own New
-
Grant·A
Chief Medical Officer
$0
65.8K sh
Own +34%
-
Grant·A
Chief Technology Officer
$0
35.4K sh
Own New
-
Grant·A
Chief Technology Officer
$0
65.8K sh
Own +403%
-
Grant·A
Chief Strategy & Legal Officer
$0
39.6K sh
Own New
-
Grant·A
Chief Strategy & Legal Officer
$0
73.7K sh
Own +52%
-
Grant·A
Mitchell Chan KEY
Chief Financial Officer
$0
39.6K sh
Own New
-
Grant·A
Mitchell Chan KEY
Chief Financial Officer
$0
73.7K sh
Own +137%
-
Other·F
Curran Simpson KEY
Chief Executive Officer
$267.2K
18.6K sh · $14.40
Own -9%
-
Other·F
Chief Medical Officer
$262.8K
18.2K sh · $14.40
Own -9%
-
Other·F
Chief Technology Officer
$17.8K
1.2K sh · $14.40
Own -7%
-
Other·F
Chief Strategy & Legal Officer
$141.0K
9.8K sh · $14.40
Own -6%
-
Grant·A
Director
—
21.1K sh
Own +10%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 29, 2026 | Jennifer Zachary | Grant A | 46.6K | $0 |
| May 29, 2026 | Jennifer Zachary | Grant A | 9.8K | $0 |
| May 29, 2026 | Daniel Tasse | Grant A | 46.6K | $0 |
| May 29, 2026 | Daniel Tasse | Grant A | 9.8K | $0 |
| May 29, 2026 | David C Stump | Grant A | 46.6K | $0 |
| May 29, 2026 | David C Stump | Grant A | 9.8K | $0 |
| May 29, 2026 | Kenneth T. Mills | Grant A | 46.6K | $0 |
| May 29, 2026 | Kenneth T. Mills | Grant A | 9.8K | $0 |
| May 29, 2026 | George V Migausky | Grant A | 46.6K | $0 |
| May 29, 2026 | George V Migausky | Grant A | 9.8K | $0 |
| May 29, 2026 | Argeris N Karabelas | Grant A | 46.6K | $0 |
| May 29, 2026 | Argeris N Karabelas | Grant A | 9.8K | $0 |
| May 29, 2026 | Alexandra Glucksmann | Grant A | 46.6K | $0 |
| May 29, 2026 | Alexandra Glucksmann | Grant A | 9.8K | $0 |
| May 29, 2026 | Allan M. Fox | Grant A | 46.6K | $0 |
| May 29, 2026 | Allan M. Fox | Grant A | 9.8K | $0 |
| May 29, 2026 | Jean Bennett | Grant A | 46.6K | $0 |
| May 29, 2026 | Jean Bennett | Grant A | 9.8K | $0 |
| May 11, 2026 | Steve Pakola 10b5-1 | Sell S | 15.3K | $168.7K |
| Apr 20, 2026 | Jean Bennett | Grant A | 24.4K | $0 |
| Mar 10, 2026 | Steve Pakola 10b5-1 | Sell S | 5.1K | $53.0K |
| Feb 1, 2026 | Steve Pakola | Other F | 5.3K | $58.8K |
| Feb 1, 2026 | Patrick J. Christmas | Other F | 4.7K | $52.5K |
| Jan 27, 2026 | Kenneth T. Mills | Exercise M | 225.0K | $0 |
| Jan 27, 2026 | Kenneth T. Mills | Other F | 221.8K | $3.0M |
| Jan 27, 2026 | Kenneth T. Mills | Exercise M | 225.0K | $2.9M |
| Jan 6, 2026 | Curran Simpson KEY | Grant A | 233.7K | $0 |
| Jan 6, 2026 | Curran Simpson KEY | Grant A | 144.9K | $0 |
| Jan 6, 2026 | Steve Pakola | Grant A | 35.4K | $0 |
| Jan 6, 2026 | Steve Pakola | Grant A | 65.8K | $0 |
| Jan 6, 2026 | Craig Malzahn | Grant A | 35.4K | $0 |
| Jan 6, 2026 | Craig Malzahn | Grant A | 65.8K | $0 |
| Jan 6, 2026 | Patrick J. Christmas | Grant A | 39.6K | $0 |
| Jan 6, 2026 | Patrick J. Christmas | Grant A | 73.7K | $0 |
| Jan 6, 2026 | Mitchell Chan KEY | Grant A | 39.6K | $0 |
| Jan 6, 2026 | Mitchell Chan KEY | Grant A | 73.7K | $0 |
| Jan 2, 2026 | Curran Simpson KEY | Other F | 18.6K | $267.2K |
| Jan 2, 2026 | Steve Pakola | Other F | 18.2K | $262.8K |
| Jan 2, 2026 | Craig Malzahn | Other F | 1.2K | $17.8K |
| Jan 2, 2026 | Patrick J. Christmas | Other F | 9.8K | $141.0K |
| Jan 1, 2026 | Jean Bennett | Grant A | 21.1K | — |
About RGNX insider trading
This page tracks insider transactions for REGENXBIO Inc. (RGNX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.